Testing STSA-1301 for immune thrombocytopenia (ITP)
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests a new drug called STSA-1301 for people with immune thrombocytopenia (ITP), a condition where the immune system attacks platelets. The study has two parts: one for healthy volunteers to check safety, and one for ITP patients to see if the drug can raise platelet counts and reduce bleeding risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- For healthy volunteers: You must be between 18 and 50 years old, have a body mass index between 18 and 26, and be in good general health.
- For ITP patients: You must be between 18 and 75 years old, have had ITP for at least 3 months, and have low platelet counts (under 30) with no severe bleeding recently.
- You must not have other serious illnesses, active infections, or a history of cancer.
- If you have ITP, you must have tried at least one standard treatment (like steroids) and it didn't work or you couldn't tolerate it.
- You must be willing to use effective birth control during the study and for 3 months after the last dose.
- You cannot have received certain other ITP treatments or blood transfusions within the past few weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two ways to raise platelet counts in people with immune thrombocytopenia (ITP) who did not get enough benefit from a short course of a standard medicine. One option is a higher dose of a similar medicine, and the other is switching to a different pill. The goal is to find a treatment that works better with fewer side effects.
This trial tests an intravenous immunoglobulin (IVIG) treatment for chronic immune thrombocytopenia (ITP), a condition where the immune system attacks platelets, causing low counts and bleeding risk. It aims to safely raise platelet levels using donated antibodies.
This trial tests a new drug called PN20 for adults with a long-term low platelet condition called immune thrombocytopenia (ITP). It aims to see if the drug can safely raise platelet counts for people who have not gotten better with other treatments.
This study tests a sequence of two medicines that help raise platelet counts in people with severe ITP. The first is given as an injection, and the second is a pill, and they are given after standard steroid treatment. The goal is to see if this approach can improve platelet levels safely.
This trial tests a combination of romiplostim (a platelet-boosting drug) and steroids as the first treatment for adults with newly diagnosed immune thrombocytopenia (ITP). It aims to see if this approach can safely and effectively raise platelet counts.
This trial tests an investigational tablet called TQB3473 against placebo for adults with primary immune thrombocytopenia (ITP) that has lasted at least a year and hasn't responded well to standard treatments. The goal is to see if the drug can safely increase platelet counts and reduce bleeding risk.
Hear when a new Primary Immune Thrombocytopenia (ITP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.